Pain Management · NSAIDSafety Signalregulatorynear-term

Aspar Pharmaceuticals recalls Ibuprofen 200mg Tablets due to foil perforations

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 12:33:55 AM

Assessment confidence: 51% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The recall of Ibuprofen 200mg Tablets by Aspar Pharmaceuticals due to foil perforations raises concerns about product quality and safety. This situation could lead to increased regulatory scrutiny and impact market confidence, necessitating careful monitoring by pharma strategy teams. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 6 ranked evidence items (1 high-relevance).

Strategic Assessment

Portfolio and strategy teams should assess the potential impact on sales and reputation, and consider strategies to mitigate risks associated with product recalls. The strongest clinical anchor is Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 1 regulatory and 2 competitive items passed relevance filtering for Aspar Pharmaceuticals Ltd.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.. This recall may impact market confidence in Aspar's product quality and could lead to increased scrutiny from regulators and competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). The recall could prompt closer regulatory oversight of Aspar Pharmaceuticals and its products, impacting future approvals and compliance requirements.

Key Risks

Elevated medium regulatory exposure for Aspar Pharmaceuticals Ltd could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The recall may affect Aspar's sales and market share, particularly if consumer trust is diminished, potentially benefiting competitors in the pain management sector.
Portfolio and strategy teams should assess the potential impact on sales and reputation, and consider strategies to mitigate risks associated with product recalls.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the recall process and any regulatory actions taken against Aspar Pharmaceuticals.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAmedium relevance
Sub-indication match (pain)
FDA document
View source
FDA AP — ACETAMINOPHEN AND IBUPROFEN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
NARA ORGANICS RECALLS ALL LOTS OF NARA INFANT FORMULA BECAUSE OF POSSIBLE HEALTH RISK
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merckmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source

Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant Erwinia in pediatrics and adolescents/young adults with acute lymphoblastic leuke
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The productivity losses due to cancer mortality and morbidity in 13 Asia-Pacific geographies across 2010, 2015, 2019, and 2022.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Commercial impact

medium

The recall may affect Aspar's sales and market share, particularly if consumer trust is diminished, potentially benefiting competitors in the pain management sector.

Regulatory impact